①imeik technology development's H1 revenue and net income growth rate has slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines such as botulinum toxins and GLP-1 drugs, the company is also expanding further in the field of medical beauty equipment.
When facing thousands of listed company announcements every day, which ones should you read? What are the key points to take away from the dozens or hundreds of pages of material announcements? Are the many professional terms in the announcements bullish or bearish? Check out Caixin's "Quick Read Announcement" column, where our reporters across the country will provide you with accurate, fast and professional interpretations on the night of the announcement.
On August 21st, Caixin reported that although imeik technology development (300896.SZ) achieved certain growth in the first half of this year, the growth rate has slowed significantly compared to before.
Tonight, imeik technology development disclosed its semi-annual report. The company achieved revenue of 1.657 billion yuan in H1, a year-on-year growth of 13.53%, and a net profit of 1.121 billion yuan attributable to shareholders of the listed company, a year-on-year growth of 16.35%.
Looking at the quarterly data, the company's revenue and net profit only saw single-digit growth in Q2, with revenue of 0.849 billion yuan, a year-on-year growth of 2.35%, and a net profit attributable to shareholders of 0.593 billion yuan, a year-on-year growth of 8.03%.
In Q1, imeik technology development achieved revenue of 0.808 billion yuan, a year-on-year growth of 28.24%, and a net profit of 0.527 billion yuan, a year-on-year growth of 27.38%.
In terms of product types, the gross margin of solution injection products, which is the main product sector of imeik technology development, centered around "Hi-body," has declined, and its proportion in total revenue has further decreased. In addition, in addition to laying out research and development pipelines such as botulinum toxins and GLP-1 drugs, the company is also expanding further in the field of medical beauty equipment.
imeik technology development attributes its business performance growth in the semi-annual report to three factors: Firstly, the social acceptance of medical beauty services continues to increase, and the industry's growth certainty is high; secondly, the significant synergy effect of the company's products reflects the competitive advantage of the product matrix; thirdly, strengthening brand building and enhancing brand influence.
From the perspective of product types, imeik technology development's revenue mainly comes from solution-based injection products and gel-based injection products with "HiTi" as the core. Among them, the revenue from solution-based injection products reached 0.976 billion yuan, an 11.65% increase from the same period last year; the revenue from gel-based injection products reached 0.649 billion yuan, a 14.57% increase from the same period last year. From the perspective of gross margin, the gross margin of solution-based injection products is 93.98%, a 1.12 percentage point decrease year-on-year, and the gross margin of gel-based injection products is 97.98%, a 0.6 percentage point increase year-on-year.
From the perspective of revenue proportion, the proportion of revenue from solution-based injection products is 58.90%, and the revenue proportion of gel-based injection products is 39.17%. Compared with the same period last year, the proportion of revenue from solution-based injection products has slightly declined.
In terms of expenses, imeik technology development's research and development investment in H1 amounted to 0.126 billion yuan, a 20.59% year-on-year increase. During the reporting period, the company achieved certain results in research and development, including the registration acceptance of type A botulinum toxin for injection for moderate to severe glabellar lines and the registration application for minoxidil lotion for hair regrowth treatment. In addition, imeik technology development has research and development pipelines in the field of sirmes peptide injection solution, injection hyaluronidase, and more.
In addition, imeik technology development is continuously expanding its layout in the medical beauty equipment field. On July 24th, imeik technology development announced that the company increased its capital in controlling shareholder Aimeichuang, raising its shareholding ratio from 40% to 52% after the capital increase. This capital increase was completed in two phases, with a total capital increase amount of 40 million yuan. It is reported that Aimeichuang owns products such as "HiBaoShui" hydrafacial device and disposable sterile injection needles.